WO2003015862A2 - Processus de traitement d'organismes biologiques - Google Patents

Processus de traitement d'organismes biologiques Download PDF

Info

Publication number
WO2003015862A2
WO2003015862A2 PCT/US2002/025183 US0225183W WO03015862A2 WO 2003015862 A2 WO2003015862 A2 WO 2003015862A2 US 0225183 W US0225183 W US 0225183W WO 03015862 A2 WO03015862 A2 WO 03015862A2
Authority
WO
WIPO (PCT)
Prior art keywords
energy
recited
electromagnetic
substrate
emitter
Prior art date
Application number
PCT/US2002/025183
Other languages
English (en)
Other versions
WO2003015862A3 (fr
Inventor
Michael L. Weiner
Robert W. Gray
Stuart G. Macdonald
Original Assignee
Biomed Solutions, Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biomed Solutions, Llc filed Critical Biomed Solutions, Llc
Priority to AU2002335628A priority Critical patent/AU2002335628A1/en
Publication of WO2003015862A2 publication Critical patent/WO2003015862A2/fr
Publication of WO2003015862A3 publication Critical patent/WO2003015862A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy

Definitions

  • United States patent 5,843,074 discloses "An improved non-coherent pulsed and colored light stimulation device used for therapeutic effects in living creatures.”
  • United States patent 5,500,009 discloses "A method of treating herpes by illuminating a herpes affected dermal zone with continuous wave (CW) non-coherent radiation emitted by at least one light emitting diode (LED), the radiation having a narrow bandwidth centered at a wavelength suitable for herpes treatment, and maintaining the light radiation for a prescribed treatment duration.”
  • CW continuous wave
  • LED light emitting diode
  • United States patent 6,246,912 discloses "A method and apparatus are provided for altering a function of tissue in a patient.”
  • the tissue affected can include that of the brain, as is disclosed in United States patent 5,983,141 ("Method and apparatus for altering neural tissue function"), which discloses "A method and apparatus for altering a function of neural tissue in a patient.
  • An electromagnetic signal is applied to the neural tissue through an electrode.”
  • Millimeter waves have wavelengths of from about 1 to about 10 millimeters, corresponding to frequencies of from about 300 to about 30 gigahertz.
  • a substantial amount of research has been conducted regarding the biological and medical effects of such millimeter waves. See, e.g., an article by A.G. Pakhomov et al. entitled “Current state and implications of research on biological effects of millimeter waves: A review of the literature,” published in 1998 in Bioelectromagnetics, 19(7), at pages 393-413.
  • millimeter wave therapy also known as “extremely high frequency therapy”
  • Today millimeter wave therapy has become an approved and accepted method of medical treatment in Russia and many former Soviet republics. More than 2,000 physicians from all over Russia have completed formal education courses in Moscow on the medical uses of millimeter waves; the method is currently used in more than 1,500 hospitals and clinics in the Russian Federation; more than 1,000,000 patients have undergone this treatment; and more than 10,000 millimeter wave devices have been sold to research and clinical institutions. See, e.g., a paper by A.Yu. Lebedeva entitled "Millimeter waves in clinical practice in Russia: a Review” that was presented on October 31, 2000 in Zvenigorod, Russia at the 12 th Russian Symposium on Millimeter Waves in Medicine and Biology.
  • FIG. 1 there is illustrated in block form an apparatus embodying the present invention.
  • the apparatus of FIG. 1 includes a variable microwave generator 10.
  • the microwave generator 10 is continuously variable over a predetermined frequency range as indicated by the arrow 11.
  • Such microwave generators are readily obtainable in the trade.
  • Model No. 440XXH represents a series of microwave generators obtainable from
  • Model No. 44076H is a millimeter wave generator having a 3 milliwatt output over a 10 gigahertz bandwidth between 60 to 90 gigahertz and includes an isolator. Other models are available with other frequency ranges and with similar power outputs.”
  • United States patent 6,101,015 discloses a microwave or millimeter wave generator.
  • United States patent 5,777,572 discloses a gyrotron oscillator millimeter wave generator for producing high power millimeter wave beams for jamming and/or damaging electronic equipment; the generator of this patent produces 20 millisecond megawatt pulses at a frequency of from 100 to 140 gigahertz.
  • United States patent 5,760,397 discloses a millimeter wave imaging system.
  • United States patent 5,507,791 discloses a millimeter wave generator producing radiation with a frequency of from 40 to 70 gigahertz.
  • United States patent 5,379,309 discloses a photonic down conversion system which employs a millimeter wave generator.
  • Millimeter wave generators devices incorporating them, and processing using them, are described in many different Russian patents. Reference may be had, e.g., to Russian patents 2122395 (method for treatment of auditory nerve neuritis), 2089166 (device for extremely high frequency therapy).
  • United States patent 5,458,130 discloses "Non-invasive therapeutic treatment and/or quantitative evaluation of musculoskeletal tissue are performed in vivo by subjecting musculoskeletal tissue to an ultrasonic acoustic signal pulse of finite duration, and involving a composite sine-wave signal consisting of plural discrete frequencies that are spaced in the ultrasonic region to approximately 2 megahertz the excitation signal is repeated substantially in the range 1 to 1000 Hz.”
  • United States patent 5,209,221 discloses "A device for generating sonic signal forms for limiting, preventing or regressing the growth of pathological tissue comprises an ultrasonic transmission system for transmitting sound waves, focused on the tissue to be treated, by way of a coupling medium.” The entire disclosure of each of these
  • Bone material may also be treated using electromagnetic and/or vibrational energies.
  • electromagnetic and/or vibrational energies e.g., pulsing electromagnetic fields are widely used by orthopedic physicians to stimulate the healing of fracture non-unions. See, e.g., the 1995 article by CAL Bassett entitled “Bioelectromagnetics in the service of medicine” published in Electromagnet Fields: Biological Interactions and Mechanisms, M. Blank editor, Advances in Chemistry Series 250, American Chemical Society, Washington D.C., pp. 261-275.
  • United States patent 5,309,898 discloses "Non-invasive therapeutic treatment and/or quantitative evaluation of bone tissue are performed in vivo, by subjecting bone to an ultrasonic acoustic signal pulse of finite duration, and involving a composite sine-wave signal consisting of plural discrete frequencies that are spaced in the ultrasonic region to approximately 2 MHz; the excitation signal is repeated substantially in the range 1 to 1000 Hz.”
  • the entire disclosure of each of these United States patents is hereby incorporated by reference into this specification.
  • Implantable medical devices are now commonplace.
  • United States patent 6,212,063 discloses "An implantable medical device such as a defibrillator is described.”
  • the entire disclosure of each of these United States patents is hereby incorporated by reference into this specification.
  • Neutralizing frequencies can usually be found and magnetic fields at these frequencies can be used to "potentize" water for therapeutic purposes.
  • the symptoms provoked electrically are similar to those provoked chemically and those provoked by the patient's environment.
  • Electrical and chemical stimuli and neutralization appear to be interchangeable.”
  • treatment of water and other bodily fluids could be included into existing internal or external devices which sample the bodily fluids. For example, insulin pumps, kidney machines, flow cytometers, and syringes.
  • Means are also available for sensing or predicting pathological disturbances or imbalances in physiological parameters. In some cases these sensors are useful in following changes in parameters during the course of treatments.
  • Transmural electrical potential differences have been suggested as an early marker for the detection of colon cancer. See the 1986 article by DA. Goller, W.F. Weidema, and R.J. Davies entitled “Transmural electrical potential difference as an early marker in colon cancer” published in Archives of Surgery 121 :345-350. Surface electrical potentials have been tested in the diagnosis of breast lesions. See the 1994 article by B.A. Weiss, G.A.P. Ganepola, H.P. Freeman, Y-S Hsu, and M . Faupel entitled "Surface electrical potentials as a new modality in the diagnosis of breast lesions—A preliminary survey” published in Breast Diseases 7:91-98). Transcranial magnetic stimulation has been used to evaluate the probable outcome of patients post-stroke. See the 2000 article by U. Ziemann entitled “Transcranial magnetic stimulation: Its current role in the evaluation of patients post-stroke” published in Neurology Report 24(3):82-93.
  • United States Patent 6,233,471 discloses a method for continually or continuously measuring the concentration of target chemical analytes present in a biological system, and processing analyte-specific signals to obtain a measurement value that is closely correlated with the concentration of the target chemical analyte in the biological system.
  • One important application of the invention involves a method for signal processing in a system for monitoring blood glucose values. The entire disclosure of each of these United States patents is hereby incorporated by reference into this specification.
  • Electromagnetic probes can be used to monitor microvascular changes taking place in response to diabetes, as is disclosed by A.S. De Nriese, J. Van de Noorde, J.J. Blom, P.M. Nanhoutte, M. Nerbeke, and ⁇ .H. Lameire in the 2000 article entitled "The impaired renal vasodilator response attributed to endothelium-derived hyperpolarizing factor in streptozotocin- -induced diabetic rats is restored by 5-methyltetrahydrofolate" published in Diabetologia 43(9): 1116-25.
  • Sympathetic skin responses following both electrical nerve and magnetic brain stimulations in insulin-dependent diabetic patients show an early yet detectable impairment of afferent pathways that takes place before the onset of peripheral neuropathy or dysautonomia, as is disclosed in a 1999 article by L. Sagliocco, F. Sartucci, O. Giampietro, and L. Murri entitled "Amplitude loss of electrically and magnetically evoked sympathetic skin responses in early stages of type 1 (insulin-dependent) diabetes mellitus without signs of dysautonomia" published in Clinical Autonomic Research: Official Journal of the Clinical Autonomic Research
  • an implantable device comprised of means for emitting and delivering energy to specific sites within a body, a programmable controller for varying the type and/or amount of energy emitted, and means for sensing a condition of a biological organism.
  • the energy emitted by the device comprises part or all of the spectra of a desired energy pattern, and it contains at least a major peak and a minor peak.
  • Figure 1 is a schematic of one preferred implantable device of this invention disposed within a patient
  • Figure 2 is a block diagram of one possible process for determining and subsequently utilization, of an energy pattern
  • Figures 3 through 8 are schematic diagrams of various arrangements of one or more implantable devices disposed within a patient
  • Figure 9 is a flow diagram of the operation of the device of Figure 4.
  • Figures 10, 11, and 12 are graphs of some of the energy patterns delivered to a patient in one of the preferred processes of this invention.
  • Figure 13 shows a shunt configuration
  • Figure 14 is a schematic showing utilization of the invention in a tube or pipe.
  • Figure 15 is a schematic showing utilization of the invention in a fluid holding vessel. Description of the preferred embodiments
  • spectral analyses is used to describe some of the properties of a specified electromagnetic energy pattern.
  • the term spectral analysis refers to the determination of the distribution of frequencies or wavelengths of transmission or absorption, or both, within the energy spectrum; it is an analytical technique for identification of materials, or of electromagnetic, vibrational, rotational frequencies. See, e.g., United States patents 6,191,417 (mass spectrometer), 6,191,271, 6,043,276, 5,902, 772, 5,814,314, 5,565,037, 5,462,751, 5,334,394, 4,997,842, and the like. The entire disclosure of each of these United States patents is hereby incorporated by reference into this specification.
  • the terms energy spectrum or spectrum or spectra or energy pattern are used in this specification. These terms refer to the set of electromagnetic, vibrational, rotational, or other energy type, pattern of frequencies. Frequencies and waveforms can be combined in different ways including, but limited to, amplitude modulation, frequency modulation, pulsating direct current, square wave, sawtooth waves, ramping, etc.) These patterns may be determined or composed by means illustrated in Figure 2.
  • One embodiment of this invention involves the application of an electromagnetic energy to an organism.
  • the organism used in the process of this invention may be, but need not be, a living biological organism.
  • the processes of this invention may be used with organs harvested from people who recently have died and wish to donate such organs.
  • the organism may be an animal organism, such as, e.g., a human being, a mammal, a reptile, and the like.
  • the organism may be a vegetable organism, such as a food crop.
  • the organism may be a virus, a bacteria, a mold, a yeast, a protozoa, and/or one or more other life forms.
  • one may treat via the process of this invention genetically modified bacteria used in cell cultures.
  • the organisms used in fermentation processes (such as, e.g., making bread, brewing alcohol) may be treated with one or more forms of energy to insure their viability and/or optimal performance.
  • FIG 1 is a schematic of one implantable device of this invention.
  • an energy emitter 16 is implanted into a biological organism 10, preferably in the proximity of an organ 12.
  • the emitter 16 emits photonic or other electromagnetic energy 14 onto organ 12.
  • the energy 14 may, e.g., be electrostatic, magnetostatic, acoustic, or very low frequency (NLF) through ultraviolet electromagnetic signals.
  • the emitter 16 is utilized to effect a process for treating the body 10.
  • the energy pattern preferably is characterized by at least one major peak and one minor peak in its spectrum.
  • the energy emitted by emitter 16 varies with time in either its f equencies and/or amplitudes and/or phases, h another preferred embodiment, the energy spectrum emitted by emitter 16 varies with time.
  • the energy emitted by emitter 16 has a spectrum with at least one major peak and one minor peak.
  • the energy emitted by emitter 16 contains at least 5 major peaks and minor peaks.
  • the energy emitted by emitter 16 has at least 10 major and/or minor peaks.
  • the energy emitted by emitter 16 is a combination of energies selected from the group consisting of photonic energy, vibratory energy, electrical energy, and mixtures thereof, provided that, in this embodiment, at least two of such energies are emitted.
  • millimeter and/or centimeter wavelength energy is used.
  • this energy has a frequency of from about 30 to about 300 gigahertz, h some papers, reference to “millimeter waves” refers to frequencies around 60 gigahertz.
  • energies of 15, 20, and 72 hertz decrease skin necrosis, stimulate capillary formation, and cause the proliferation of fibroblasts.
  • energies of 25 and 50 hertz promote synergistic effects with nerve growth factor.
  • the use of energies from about 1 to about 100 hertz promotes healing of many bodily parts.
  • Resistant myofascial pain can be treated with microcurrent of specific frequencies, as is disclosed in a 1998 article by C. McMakin entitled “Microcurrent treatment of myofascial pain in the head, neck, and face” published in Topics in Clinical Nursing 5(l):29-35.
  • Chronic wounds can be treated by electric and electromagnetic fields, as is disclosed in a 1992 article by L. Nodovink and R. Karba entitled “Treatment of chronic wounds by means of electric and electromagnetic fields. Part 1. Literature review” published in Medical and Biological Engineering &_Computing 30:257-266.
  • a variety of soft tissues have been treated with pulsing electromagnetic fields and 27 megahertz electromagnetic frequencies, as is disclosed by B.F. Sisken and J.
  • Laser acupuncture has been used to treat paralysis in stroke patients, as is disclosed by M.A. ⁇ aeser, M.P. Alexander, D. Stiassny-Eder, V. Galler, J. Hobbs, D. Bachman, and L. ⁇ . Lannin in 1995 in an article entitled "Laser Acupuncture in the Treatment of Paralysis in Stroke Patients: A CT Scan Lesion Site Study" published in the American Journal of Acupuncture 23(l):13-28.
  • the use of energies from about 1 to about 100 hertz promotes healing of many bodily parts, with some studies showing effects at much higher frequencies into the terahertz range.
  • Millimeter waves are being utilized for the treatment of pain as disclosed by A.A.
  • United States Patent 4,528,256 discloses that cells can be modified "by subjecting them to the influence of ions from a metal electrode, for example of silver, which is placed in contact with them and which is made electrically positive, causing low intensity direct current to flow through them.
  • the cells which are relatively specialized, such as normal mammalian fibroblasts, assume a simpler, relatively unspecialized form and come to resemble hematopoetic or marrow-like cells.”
  • the process leads to improved therapeutic effects, "such as enhanced cell or biochemical production, enhanced lesion healing, enhanced normal tissue growth or regeneration, cell dedifferentiation, changing cancer cell form, and stopping multiplication of cancer cells.”
  • the entire disclosure of this patent is hereby incorporated by reference into this specification.
  • a light source called the MFbio-spectrum lamp treatment has been successful in treatment of diabetes, as is disclosed by G. Wu in 2000 in an article published on the web at http://www.findheak.com/mall/telstar/clinic/diabetes.php3).
  • Pulsed electromagnetic fields are being used to stimulate cutaneous wound healing in diabetic rats, as is disclosed by O. Patino,
  • Pulsating high-frequency electromagnetic fields are being used to treat patients with diabetic neuropathies and angiopathies, as is disclosed by V. Vesovic-Potic and S. Conic in a
  • Electromagnetic stimulation of the rat pancreas lowers serum glucose levels in rats, as is disclosed by P.O. Milch, J.B. Ott, R.J. Kurtz, and E. Findl in a 1981 article entitled "Electromagnetic stimulation of the rat pancreas and the lowering of serum glucose levels" published in Transactions - American Society for Artificial Internal Organs
  • ⁇ on-invasive electromagnetic flowmetry using external magnets and flowmetry by ⁇ MR are being used for screening for arterial diseases, monitoring of the treatment, and study of hardened arteries in diabetes, as is disclosed by H. Boccalon in 1989 in an article entitled "The necessary advantage of measuring the pulsatile arterial flow of the limbs in patients with arterial disease” published in Annales de Cardiologie et d Angeiologie
  • the energy utilized in the process of this invention has a frequency of at least 1,000 gigahertz (one terahertz) and is believed to cause deoxyribonucleic acid to resonate.
  • a multiplicity of different frequencies are used.
  • Figure 2 is a flow diagram which illustrates one preferred embodiment of the energy pattern determination process of this invention.
  • the spectrum of a therapeutic agent is determined by spectral analysis, or by reference to standard tables of the spectrum of the agent.
  • the entire disclosure of each of these United States patents is hereby incorporated by reference into this specification. Reference also may be had, e.g., to John A. Dean's "Analytical Chemistry Handbook"(McGraw-Hill, Inc., New York, 1995).
  • step 11 the spectrum of a chemical agent is determined ex vivo, outside of a biological organism.
  • a drug within a biological organism will change its physical and/or chemical identity, due to dissolution in one or more solvents and/or reaction with one or more agents within the body. As the physical and chemical properties of the drug change, so does its spectrum.
  • the set of drug compounds available to the medical community is limited by available chemical synthesis technology, and by precursor chemical structures available from organic, inorganic, botanical, or animal sources. Thus there is a practical limit to the array of signal molecules that can be used to elicit a cellular response.
  • the cells themselves, and the receptor sites in particular, are under no such restriction.
  • electromagnetic spectra that have no corresponding available synthesized chemical structure, but which spectra may have effective, and even superior, therapeutic affect at the desired receptor site when used in the manner described in this invention.
  • One approach to determine the specific receptor spectrum is to excite the receptor with an ultra short energy pulse, measure the resulting spectrum, and perform a mathematical transform on the resulting spectrum to determine the ideal-fit complementary spectrum that would be associated with the ideal-fit chemical compound.
  • This approach shall be referred to as 'receptor response spectrum development' for descriptive purposes and is included in Figure 2, step 15.
  • electromagnetic signals can be designed on the basis of highly specific information on the structure and operation of receptor sites on and within cells. The growing information on the molecular configurations of receptors and on the mechanisms taking place when ligands interact with receptors provides a wealth of opportunities for the design of highly specific electromagnetic therapies. We now know that what has been referred to in the past as
  • a receptor can actually have several functional domains. There is a ligand-binding domain and an effector domain.
  • the ligand-binding domain is the specific site, often on the cell surface, where a regulator ligand (such as a hormone, growth factor, or neurotransmitter) has its primary action.
  • the effector domain consists of a series of intermediary cellular molecules in the signal transduction pathway. Drugs and electromagnetic fields can interact with both of these domains, including the domains of the second messenger molecules that convey messages within cells. Recent advances in computational chemistry, structural analysis of organic compounds, and biochemical measurement of the primary actions of drugs at their receptors have permitted the design of new and more specific drugs. The same information can be used in the de novo design of highly specific electromagnetic interventions.
  • step 17 one may determine a therapeutic energy pattern by subjecting the body and/or individual organs, tissues, bodily fluids, cells, cells in culture to various energy patterns and recording the response.
  • step 17B one may determine a therapeutic energy pattern by measuring the energy patterns of a healthy body, and/or individual organs, tissues, bodily fluids, cells. Additionally, the energy patterns emitted by the body as one is placed into various meditative states may be recorded.
  • the hands e.g., can emit a range of electromagnetic frequencies from about 0.3 hertz to 30 hertz (see, e.g., an article by J. Zimmerman, 1985 "New technologies detect effects of healing hands” published in Brain Mind Bulletin 10 (September 30 issue, p. 3)). As disclosed by Zimmerman, the emitted electromagnetic energy may sweep through this frequency range rather than being a fixed frequency.
  • a desired energy spectrum, or portion thereof, or combination of one or more such spectra may be evaluated in step 19 against other candidate spectra.
  • the response of a biological body, or a portion thereof, can be determined, and a correlation can be made between the use of a specified spectrum and/or spectra and the response of the organism.
  • a spectrum and/or spectra may be selected for any particular condition to be treated in the biological organism; and information about this selected spectrum/spectra may be incorporated into a program in step 23.
  • the program may be incorporated into a device which is capable of sensing the condition within the biological organism, selecting the appropriate spectrum/spectra from its database, emitting such energy pattern and directing it to the appropriate site within the organism, sensing the response of the living organism to such emission, modifying such emission as appropriate, and/or ceasing such emission as appropriate.
  • portion 27 of the process which is comprised of steps 11 through 25, the steps necessary to identify the appropriate energy pattern are described.
  • portion 29 of the process comprising steps 31 through 37, the steps necessary to apply the selected energy pattern to the living organism are described.
  • step 31 of the process which is optional, one may utilize an external momtor/reprogrammer for bi-directional communication between the implanted device and the outside world.
  • a momtor/reprogrammer for bi-directional communication between the implanted device and the outside world.
  • the external monitor/reprogrammer is operatively connected to the implanted energy device of step 33 which, in response to external stimuli and/or in vivo stimuli provided by the biological organism, provides energy to biological organism of step 35.
  • a sensor which can monitor the response of the living organism to the applied energy and, with use of a programmable computer (not shown), continually modifies the energy delivered to the organism.
  • the connection between the external monitor/reprogrammer 31 and the energy device may be direct, or it may be indirect. In one embodiment, the connection is indirect and is made, e.g., by means of transceivers.
  • an emitter 26 is attached to the end of a catheter 24 and is controlled by a controller 28.
  • the catheter is inserted into body 10 through an incision 22.
  • the organ 20 is then irradiated with the electromagnetic energy 30.
  • An operator may control the electromagnetic energy by adjusting parameters of the controller 28.
  • an emitter 16 is an augmentation module connected to an implanted heart pacemaker 40; in the embodiment, the pacemaker 40 is connected via lead 42 to the heart 12.
  • This augmentation module may be attached to the pacemaker 40 at any future date after the pacemaker 40 has been implanted without removal or otherwise replacement of the original pacemaker 40.
  • the augmentation module may be implanted at the same time as the pacemaker 40. In either situation, the augmentation unit may be detached from the pacemaker 40 and removed from the body 10 at any time without significant disruption of the pacemaker 40.
  • a controller with a programmable logic unit 44 is connecter to the emitter 16 and the pacemaker 40. The controller
  • the 44 also has communication means 48 to implanted sensors 46.
  • the emitter 16 may be activated by the analyses of the sensors' input and comparison to threshold conditions or comparison to a programmable database of deleterious conditions.
  • the emitted energy 14 may be adjusted from very low frequency to ultraviolet or terahertz range frequency programmatically through the controller's programmable logic unit 44.
  • the emitted electromagnetic or vibrational energy signals produced by the augmentation modules may be a reproduction of the natural energy signals emitter from a healthy organ. In this way, a healthy signal may reinforce a non-healthy organ as well as to propagate a healthy signal to other organs.
  • the sensors 46 are capable of determining the electromagnetic pattern and/or other physiological and/or biochemical and/or biophysical parameter of any portion of the body 10 while such body is functioning.
  • One may determine the electromagnetic pattern of such body when, e.g., the liver is functioning properly.
  • One may determine the electromagnetic pattern of such body when, e.g., the liver is not functioning properly.
  • One may, e.g., determine the electromagnetic pattern of the heart in relation to diagnostic indicators of susceptibility to arrhythmias of various kinds.
  • One may, e.g., determine the electromagnetic pattern of such body when the liver is exposed to one or more drugs, or to heat, or to any treatment. By making these measurements, one can correlate the optimum performance of, e.g., the liver with optimum electromagnetic patterns. Similar correlations can be made with other organs and/or bodily processes.
  • the sensors 46 can determine when, e.g., the liver is malfunctioning and deliver the required electromagnetic radiation to the patient, either alone and/or in combination with one or more drugs, until the liver is functioning properly.
  • an implantable drug dispenser 240 is operatively connected to the controller 44 and, as required, delivers one or more drugs in response to the commands of such controller 44.
  • the process depicted in Figure 9 may be effected by the device depicted in Figure 4.
  • the sensors 46 are so constructed and situated as to detect energy patterns in the environment, external to the body 10. Controller 44 can analyze such patterns and can determine if such external energy patterns are disruptive to the body 10 or to the treatment currently administered.
  • the controller 44 may change the energy pattern emitted from emitter 16 or halt the administration of treatment until the disruptive external energy patterns are no longer detected and/or notify the patient through communications device 41 using communication channel 43.
  • Communications channel 43 may be, e.g. by radio frequency means.
  • the sensors 46 are so constructed and situated as to detect disturbances in the interplanetary and/or geomagnetic fields that have been correlated with vulnerability to myocardial infarction, cardiac arrhythmias, stroke, seizures, depression, and mortality in general, as is disclosed by Y.I. Gurfinkel, V.N.
  • Controller 44 can analyze such environmental patterns and can determine if such patterns are disruptive to the body 10 or to the treatment currently administered. If such a disruptive external energy pattern is detected, the controller 44 may change the energy pattern emitted from emitter 16, halt the administration of treatment until the disruptive external energy patterns are no longer detected, introduce a protective energy pattern such as an enhanced pacemaker signal, and/or notify the patient through communications device 41 using communication channel 43.
  • a protective energy pattern such as an enhanced pacemaker signal
  • an emitter 16 implanted in body 10 emits electromagnetic energy 14 onto or within an organ 12.
  • a probe 62 with an emitter 64 at the insertion tip of a catheter is inserted into the body 10 through incision 68.
  • the inserted probe emitter 64 emits electromagnetic energy 66 onto the organ 12 from a different orientation than that of emitter 16.
  • the electromagnetic energy 66 which is emitted from the probe emitter is controlled via controller 60 and need not have the same characteristics as the electromagnetic energy emitted from emitter 16.
  • Figure 6 illustrates an embodiment in which an emitter 16 implanted in body 10 emits electromagnetic energy 14 onto an organ 12, and an external device 80 delivers vibratory energy 82 to the organ 12.
  • emitter 16 continually emits energy
  • external device 80 intermittently emits energy.
  • Other external devices 81 and 83 may also deliver various energy patterns to the body 10.
  • electromagnetic energy may be delivered through a device located outside of the patient's body, such as a watch 81 and/or external appliances 80 and/or 83 and/or in glasses frames (not shown) ankle bracelets (not shown), etc.
  • a device located outside of the patient's body such as a watch 81 and/or external appliances 80 and/or 83 and/or in glasses frames (not shown) ankle bracelets (not shown), etc.
  • an electromagnetic emitter 16 implanted in body 10 emits electromagnetic energy 14 onto an organ 12.
  • a vibrational energy emitter 90 is also implanted into body 10 and delivers vibrational energy 94 to organ 92.
  • the emitter 90 also consists of a sensor element.
  • other sensor devices 96 are implanted into body 10. All of such implanted devices are in communication through communication channels 98 to form a network.
  • the communication means may be through fiber optic cables, wires, shielded wires, wireless or other means.
  • the implanted devices 16 and 90 are so constructed as to contain programmable logic units suitable for analyzing signals from other implanted devices and from sensors 96 and to initiate the adjustment of adjustable parameters of any implanted device in the network.
  • the emitters are so designed as to allow for multiple frequencies and intensities to be emitted at the same time including a carrier and pulsed waves combined.
  • Each of these implanted devices is so constructed as to allow the addition of other implanted or external devices or the removal of said devices from the network of devices without the interruption of other devices in the network.
  • the interconnection of these devices may be made by conventional means. See, e.g.,
  • bodily fluid is withdrawn from body 10 via line 104, treated with energy in device 100, and returned to the body via line 102.
  • a portion of the bodily fluid may be segregated in device 100 and treated separately from the other bodily fluid.
  • the device 100 may comprise a flow cytometer which identifies cancerous cells, segregates them, treats them with high heat and/or radiation, and returns some or all of the cells so treated to the body.
  • the electromagnetic energy is delivered directly into one or more bodily fluids, such as, e.g., the blood, the lymph, the urine, cerebrospinal fluid, endolymph, aqueous humor, etc.
  • bodily fluids such as, e.g., the blood, the lymph, the urine, cerebrospinal fluid, endolymph, aqueous humor, etc.
  • FIG 9 is a flow diagram of one preferred process.
  • the emitter controller 16 (not shown) checks the blood pressure of the biological organism using, e.g., sensors 46 (see Figure 4). If the blood pressure of the organism is lower than a specified level, in step 104 the process is aborted If the blood pressure of the organism is higher than such specified level, then in step 106 the controller (not shown) optionally checks other body parameters (such as, e.g., body temperature, pulse rate, etc.) to determine whether it is safe to apply to specified therapy.
  • body parameters such as, e.g., body temperature, pulse rate, etc.
  • step 108 millimeter wave frequency is applied for a specified duration such as, e.g., 15 minutes.
  • the blood pressure of the biological organism is again checked in step 102'.
  • additional incremental treatments 110 preferably are continued up to a threshold decision point 112.
  • additional chemical therapy is administered in step 114, and monitored in step 102". If this additional drug therapy is not effective, the patient is alerted in step 118.
  • step 9 Another preferred embodiment is in the regulation of carbohydrate metabolism in the diabetic patient.
  • the sensor in step 102 monitors the concentration of glucose in the blood and millimeter or other frequencies are emitted in step 108 to effect a stimulation of glucose absorption in the tissues in the body.
  • additional incremental treatments 110 preferably are continued up to a threshold decision point 112.
  • additional electromagnetic energy is administered in step 108 or additional chemical therapy is administered in step 114, and monitored in step 102". If this additional electromagnetic or drug therapy is not effective, the patient is alerted in step 118.
  • the entire configuration, or suitable variations of it, constitute what has been termed an "artificial pancreas.”
  • Figure 10A is a graph of a spectrum 200 of one preferred energy pattern delivered from the emitter 16 to a patient 10 at "time zero."
  • frequency is plotted on the horizontal axis 202
  • amplitude is plotted on the vertical axis 204.
  • the spectrum 200 is comprised of major peaks 206, 207 and 208 and minor peaks 210, 212, and 214.
  • the spectrum of the energy emitted by emitter 16 in this embodiment will contain at least two major peaks and two minor peaks.
  • the spectrum 216 depicted in the graph of Figure 10B is illustrative of the pattern emitted by the same emitter 16 at some time, tl, after "time zero.” As will be apparent, in this embodiment, the spectrum 216 differs from the spectra 200.
  • the energy pattern delivered by the emitter 16 is substantially comparable to the energy pattern delivered by a drug as it undergoes physical and/or chemical changes within the patient's body.
  • the computer is programmed such that the emitter will continue to deliver the same energy pattern to a biological organism as the drug did when the drug was first administered to the patient.
  • the apparatus depicted in Figure 4 one may monitor the reaction of a patient's body to the administration of electromagnetic energy from the emitter and/or the administration of one or more drugs.
  • the response of the patient's body to various portions of such energy patterns may be determined by the sensors 46 and the controller 44. In many cases, it will be determined that a certain portion of the spectral pattern, and/or its combination with one or more drugs, advantageously affects the patient's body. In other cases, it may be determined that a certain portion of the spectral pattern, and/or its combination with one or more drugs, disadvantageously affects the patient's body.
  • the device of Figure 4 will be capable of determining, at any particular point in time, which portion, if any, of the energy pattern and/or drug should be applied at that point in time. Thereafter, by monitoring the patient's reaction to the administered energy pattern(s) and/or drug(s), the controller 44 can cause the emitter 16 or the implantable drug dispenser 240 connected to the controller 44 to modify the energy pattern(s).
  • the emitter 16 may emit one or more interfering and/or phase shifted and/or phase inverted and/or complementary energy patterns which, after they interact with the energy pattern produced by such drug, or with the response of the receptor molecules the drug is acting upon, produce the desired energy pattern and/or lack thereof.
  • Figure 11 A illustrates a spectrum 220.
  • the controller 44 will cause emitter 16 to emit only the major peaks 222, 224, and 226.
  • the major peaks is the cause of deleterious effects, in which case these major peaks are removed from the emitted spectrum.
  • the process of this invention is not limited to the use of only one emitter 16 or only one implantable drug dispenser 240.
  • the use of a multiplicity of emitters 16 allows one to produce a large variety of different waveforms and spectra patterns that can interact with a multiplicity of injected drugs.
  • Figures 12A and 12B illustrate the spectral patterns 300 and 302 which may be produced at one particular point in time by emitters 16 and 64 (see Figure 5).
  • an apparatus for treating a biological organism comprising an externally worn and removable appliance comprised of means for inducing an electromagnetic and/or vibrational and/or light and/or other energy pattern of a biological process and/or a suitable drug or drugs through the skin of a organism which, preferably, is living, hi this embodiment, the energy pattern corresponds to at least a portion of the electromagnetic pattern, or a modification thereof, of a biological process within the organism.
  • a process comprising the steps of determining a first electromagnetic pattern of a biological process within a living organism, determining a second electromagnetic pattern of a biological process within a living organism, introducing said first electromagnetic pattern into said living organism, and introducing said second electromagnetic pattern into said living organism.
  • more than two such electromagnetic patterns may be administered, and they may be administered in combination with one or more drugs.
  • the electromagnetic energy and/or other energy is delivered directly into cartilage, hi another embodiment of the invention, the electromagnetic and/or other energy is delivered directly into bone.
  • the electromagnetic and/or other energy is delivered directly into brain cells, hi yet another embodiment of this invention, the electromagnetic and/or other energy is delivered to fascia and/or cerebrospinal fluid and/or other fluids. In yet another embodiment of this invention, the electromagnetic and/or other energy is delivered to acupuncture and/or other biologically active points within and/or on the body.
  • a desired electromagnetic spectrum and/or modulated light or sound is adapted to provide anti- allergy signals, anti-aids recognition signals, signals that reduce the side effects of drugs, signals that mimic the signals of homeopathic remedies, signals that mimic the patterns of heat drugs (such as beta blockers), nitrolycerine, anti-tumor drugs, antibiotics, antiviral agents, stress reducing agents, pain killers, and the like.
  • the spectral pattern which exists when the AIDS virus attaches to a lymphocyte is determined, and a pattern designed to interfere with this first spectral pattern is emitted.
  • a pattern designed to interfere with this first spectral pattern is emitted.
  • either the viron itself and/or a component of the viron is caused to resonate at its natural coherent resonant frequency.
  • Two key elements of such viron are two surface proteins, glycoprotein GP41 and glycoprotein GP 120; they constitute a dielectric antenna.
  • the emitter 16 is comprised of means for transmitting a desired electromagnetic pattern to a pacemaker.
  • a pacemaker e.g., one may transmit suitable analog, digital, or scalar versions of such signals to a cardiac assist device.
  • the cardiac assist device is adapted to store the spectrum transmitted to it by the emitter 16 and, when appropriate, to retransmit part or all of such spectrum.
  • an emitter is built into a shunt.
  • a blood artery or vein is divided into two parts 330, 332 and a filter/separator 334 is inserted between them.
  • Arrows 331, 337, 339, 341 show the direction of fluid flow.
  • the filter/separator 334 diverts a portion for the plasma into line 336. That portion of the blood fluid which is not diverted to 336 is returned to the artery or vein 332.
  • the divert plasma enters an emitter chamber 338 where the energy pattern is applied to the plasma. Said energy pattern may be millimeter wave, acoustic energy, light, etc. as describe throughout this disclosure.
  • the treated plasma returns to the artery or vain through line 340.
  • 334, 336, 338 may be components of an artificial heart implant into the body.
  • tubing 350 carrying a fluid 353 flowing in the direction 354 has an emitter 358 implanted through the tubing wall so that the emitter tip 356 is in contact with the fluid 352.
  • said tubing 350 may be the fuel line of a vehicle, the water supply line to a faucet, the outlet of a water dispenser, an intravenous (IN) line, an implanted stent, etc.
  • the emitter 358 is connected to a controller 362 by communications means 360 which may be, e.g., a wire, fiber optics cable, RF or other means.
  • the controller 362 controls the type of energy, pattern of energy, application timing, duration, magnitude and/or other adjustable parameters. Additionally, a optional sensor 364 may be inserted into the tubing. Said sensor 364 may measure, e.g., the flow rate of the fluid 352 and/or the temperature of the fluid 352, the pH level of the fluid 352 and/or other measurable properties. Said sensor is connected to controller 362 by communication means 366 which may be, e.g. a wire, fiber optic cable, RF or other means.
  • the emitter tip 356 of Figure 14 is attached externally to the tubing wall 350. In this embodiment, the emitter tip 356 does not come into direct contact with the fluid 352.
  • the fluid 372 to receive the energy pattern treatment is preferably contained in a vessel 370 which has means 371 for removing and/or replenishing said fluid 372.
  • said vessel 370 may be e.g., a hot water heater, a thermos or canteen, a coffee maker, an IV bag, a gasoline tank, etc.
  • emitter 374 has its emitting tip 376 in contact with fluid 372. hi another embodiment (not shown) the emitter tip 376 is external to the vessel 370.
  • the emitter 374 is connected to controller 380 via communication means 378 which may be, e.g., a wire, fiber optics cable, RF or other means.
  • the controller 380 controls the type of energy, pattern of energy, application timing, duration, magnitude and/or other adjustable parameters. Additionally, a optional sensor 382 may be inserted into the vessel 370. Said sensor 382 may measure, e.g., the temperature of the fluid 372, the pH level of the fluid 372 and/or other measurable properties. Said sensor 382 is connected to controller 380 by communication means 384 which may be, e.g. a wire, fiber optic cable, RF or other means.

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Radiology & Medical Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne un appareil destiné à traiter un substrat contenant un dispositif qui émet et distribue de l'énergie à ce substrat, un contrôleur programmable destiné à modifier le type et/ou la quantité d'énergie émise et un appareil de détection d'un état du substrat. L'énergie émise par cet appareil comprend au moins une partie du spectre d'un diagramme d'énergie recherché et contient au moins une crête majeure et une crête mineure.
PCT/US2002/025183 2001-08-15 2002-08-12 Processus de traitement d'organismes biologiques WO2003015862A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002335628A AU2002335628A1 (en) 2001-08-15 2002-08-12 Process for treating biological organisms

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US93036401A 2001-08-15 2001-08-15
US09/930,364 2001-08-15

Publications (2)

Publication Number Publication Date
WO2003015862A2 true WO2003015862A2 (fr) 2003-02-27
WO2003015862A3 WO2003015862A3 (fr) 2003-12-04

Family

ID=25459258

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/025183 WO2003015862A2 (fr) 2001-08-15 2002-08-12 Processus de traitement d'organismes biologiques

Country Status (2)

Country Link
AU (1) AU2002335628A1 (fr)
WO (1) WO2003015862A2 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006106132A1 (fr) * 2005-04-06 2006-10-12 Friederike Scharmer Dispositif electromedical implantable ou extracorporel pour le traitement d'organes et la surveillance d'organes et procede de traitement therapeutique d'organes
US11185687B2 (en) 2005-04-06 2021-11-30 Berlin Heals Gmbh Electromedical implantable or extracorporeally applicable device for the treatment or monitoring of organs, and methods for therapeutic organ treatment

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5528652A (en) * 1990-09-05 1996-06-18 Photoelectron Corporation Method for treating brain tumors
US5993378A (en) * 1980-10-28 1999-11-30 Lemelson; Jerome H. Electro-optical instruments and methods for treating disease
US6119089A (en) * 1998-03-20 2000-09-12 Scientific Learning Corp. Aural training method and apparatus to improve a listener's ability to recognize and identify similar sounds
US6124937A (en) * 1996-11-15 2000-09-26 Optosens Optische Spektroskopie Und Sensortechnik Gmbh Method and device for combined absorption and reflectance spectroscopy
US6144878A (en) * 1995-12-11 2000-11-07 Intermedics Inc. Implantable medical device responsive to heart rate variability analysis
US6208894B1 (en) * 1997-02-26 2001-03-27 Alfred E. Mann Foundation For Scientific Research And Advanced Bionics System of implantable devices for monitoring and/or affecting body parameters
US6221095B1 (en) * 1996-11-13 2001-04-24 Meditech International Inc. Method and apparatus for photon therapy
US6447461B1 (en) * 1999-11-15 2002-09-10 Sound Id Method and system for conducting a hearing test using a computer and headphones

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5993378A (en) * 1980-10-28 1999-11-30 Lemelson; Jerome H. Electro-optical instruments and methods for treating disease
US5528652A (en) * 1990-09-05 1996-06-18 Photoelectron Corporation Method for treating brain tumors
US6144878A (en) * 1995-12-11 2000-11-07 Intermedics Inc. Implantable medical device responsive to heart rate variability analysis
US6221095B1 (en) * 1996-11-13 2001-04-24 Meditech International Inc. Method and apparatus for photon therapy
US6124937A (en) * 1996-11-15 2000-09-26 Optosens Optische Spektroskopie Und Sensortechnik Gmbh Method and device for combined absorption and reflectance spectroscopy
US6208894B1 (en) * 1997-02-26 2001-03-27 Alfred E. Mann Foundation For Scientific Research And Advanced Bionics System of implantable devices for monitoring and/or affecting body parameters
US6119089A (en) * 1998-03-20 2000-09-12 Scientific Learning Corp. Aural training method and apparatus to improve a listener's ability to recognize and identify similar sounds
US6447461B1 (en) * 1999-11-15 2002-09-10 Sound Id Method and system for conducting a hearing test using a computer and headphones

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006106132A1 (fr) * 2005-04-06 2006-10-12 Friederike Scharmer Dispositif electromedical implantable ou extracorporel pour le traitement d'organes et la surveillance d'organes et procede de traitement therapeutique d'organes
US9457184B2 (en) 2005-04-06 2016-10-04 Berlin Heals Holding Ag Electromedical implantable or extracorporeally applicable device for the treatment or monitoring of organs, and method for therapeutic organ treatment
US11185687B2 (en) 2005-04-06 2021-11-30 Berlin Heals Gmbh Electromedical implantable or extracorporeally applicable device for the treatment or monitoring of organs, and methods for therapeutic organ treatment

Also Published As

Publication number Publication date
AU2002335628A1 (en) 2003-03-03
WO2003015862A3 (fr) 2003-12-04

Similar Documents

Publication Publication Date Title
US20050203578A1 (en) Process and apparatus for treating biological organisms
US8494625B2 (en) Methods and apparatus for electrical stimulation of tissues using signals that minimize the effects of tissue impedance
US4723536A (en) External magnetic field impulse pacemaker non-invasive method and apparatus for modulating brain through an external magnetic field to pace the heart and reduce pain
US7311722B2 (en) Photodynamic stimulation device and methods
US20080058793A1 (en) Electromagnetic apparatus for prophylaxis and repair of ophthalmic tissue and method for using same
EP1094864B1 (fr) Procede et dispositif permettant de stimuler le systeme immunitaire et d'induire la guerison au niveau cellulaire
CN107072821A (zh) 用于损伤或患病组织的非侵入性治疗的多波长光疗装置、系统和方法
US20030171640A1 (en) Electromagnetic method of treatment of lesions associated with inadequate blood perfusion, partial denervation, tissue loss, pain, edema, inflammation and infection
JP2002511323A (ja) フォトマトリックス・デバイス
JP2008538513A (ja) 薬物、化学物質、及び局所薬の増強装置、並びにその使用方法
KR20030040355A (ko) 생체조직의 생물학적 기능들을 정상화하는 방법 및 생체조직에 전자기를 작용시키는 장치
BRPI0810084B1 (pt) sistema eletrônico ativável por energia elétrica para uso na inibição do crescimento de células cancerosas ou na proliferação das mesmas em um indivíduo mamífero de sangue quente
Moskvin et al. Laser blood illumination. The main therapeutic techniques
US20080234535A1 (en) Device and method for thrombosis and pulmonary embolism
EP2194579A2 (fr) Dispositif de régulatin de processus physiologiques dans un objet biologique
US20120185016A1 (en) Process and apparatus for treating biological organisms
CN101448549A (zh) 利用辐射能量的组织体的处理
WO2003015862A2 (fr) Processus de traitement d'organismes biologiques
Dong et al. Modulation effect of mouse hippocampal neural oscillations by closed-loop transcranial ultrasound stimulation
US20200289841A1 (en) System and method for therapeutic treatment using light and pulse modulation
Gáspár Professor Endre Mester, the father of photobiomodulation
RU2334458C2 (ru) Способ лечения эректильной дисфункции
RU2209097C1 (ru) Устройство для электромагнитной терапии
Rubik The unifying concept of information in acupuncture and other energy medicine modalities
JP3396849B2 (ja) 生体内の検査装置

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CR CU CZ DE DK DZ EE ES FI GB GD GE GH GM HR ID IL IN IS JP KE KG KP KR KZ LC LR LS LT LU LV MA MD MG MK MN MX MZ NO NZ OM PH PL PT RO RU SE SG SI SK SL TJ TM TR TT TZ UA US UZ VC VN YU ZA ZM

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE BG CH CY CZ DK EE ES FI FR GB GR IE IT LU MC PT SE SK TR BF BJ CF CG CI GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase in:

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP